Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir.
Chen X, Huang X, Ma Q, Kuzmič P, Zhou B, Zhang S, Chen J, Xu J, Liu B, Jiang H, Zhang W, Yang C, Wu S, Huang J, Li H, Long C, Zhao X, Xu H, Sheng Y, Guo Y, Niu C, Xue L, Xu Y, Liu J, Zhang T, Spencer J, Zhu Z, Deng W, Chen X, Chen SH, Zhong N, Xiong X, Yang Z.
Chen X, et al. Among authors: li h.
Nat Microbiol. 2024 Apr;9(4):1075-1088. doi: 10.1038/s41564-024-01618-9. Epub 2024 Mar 29.
Nat Microbiol. 2024.
PMID: 38553607
Free PMC article.